JP2021523200A5 - - Google Patents
Info
- Publication number
- JP2021523200A5 JP2021523200A5 JP2020564158A JP2020564158A JP2021523200A5 JP 2021523200 A5 JP2021523200 A5 JP 2021523200A5 JP 2020564158 A JP2020564158 A JP 2020564158A JP 2020564158 A JP2020564158 A JP 2020564158A JP 2021523200 A5 JP2021523200 A5 JP 2021523200A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671985P | 2018-05-15 | 2018-05-15 | |
| US62/671,985 | 2018-05-15 | ||
| PCT/US2019/032289 WO2019222266A1 (en) | 2018-05-15 | 2019-05-14 | Magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523200A JP2021523200A (ja) | 2021-09-02 |
| JP2021523200A5 true JP2021523200A5 (enExample) | 2022-06-01 |
Family
ID=68534223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564158A Ceased JP2021523200A (ja) | 2018-05-15 | 2019-05-14 | Ｍａｇｌ阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11332453B2 (enExample) |
| EP (1) | EP3793547A4 (enExample) |
| JP (1) | JP2021523200A (enExample) |
| KR (1) | KR20210010475A (enExample) |
| CN (1) | CN112088001A (enExample) |
| AR (1) | AR115092A1 (enExample) |
| AU (1) | AU2019271123A1 (enExample) |
| BR (1) | BR112020000863A2 (enExample) |
| CA (1) | CA3097063A1 (enExample) |
| CL (1) | CL2020002927A1 (enExample) |
| CO (1) | CO2020013550A2 (enExample) |
| CR (1) | CR20200545A (enExample) |
| DO (1) | DOP2020000207A (enExample) |
| EA (1) | EA202092586A1 (enExample) |
| GE (2) | GEP20227443B (enExample) |
| JO (1) | JOP20200276A1 (enExample) |
| MA (1) | MA52635A (enExample) |
| MX (1) | MX2020012158A (enExample) |
| NI (1) | NI202000080A (enExample) |
| PE (1) | PE20211385A1 (enExample) |
| PH (1) | PH12020551934A1 (enExample) |
| SG (1) | SG11202011228TA (enExample) |
| TW (1) | TW201946906A (enExample) |
| WO (1) | WO2019222266A1 (enExample) |
| ZA (1) | ZA202006327B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JP6899975B2 (ja) | 2018-05-14 | 2021-07-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ−１阻害剤 |
| MA52635A (fr) * | 2018-05-15 | 2021-03-24 | H Lundbeck As | Inhibiteurs de magl |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| MX2020012760A (es) | 2018-06-27 | 2021-03-25 | Hoffmann La Roche | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. |
| EP3814328B1 (en) | 2018-06-27 | 2026-03-11 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2 |
| SG11202108008PA (en) * | 2019-01-25 | 2021-08-30 | H Lundbeck As | Methods of treating disease with magl inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| BR112021013917A2 (pt) * | 2019-11-15 | 2022-05-24 | H Lundbeck As | Forma cristalina de um inibidor de magl, composição farmacêutica e uso |
| CA3294692A1 (en) | 2019-11-26 | 2026-03-02 | Gilead Sciences, Inc. | Processes and intermediates for preparing mcl1 inhibitors |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| US12202782B2 (en) | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| CN118715211A (zh) | 2022-02-17 | 2024-09-27 | 巴斯夫欧洲公司 | 杀有害生物活性氨硫脲化合物 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| AU3226993A (en) | 1991-11-27 | 1993-06-28 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| DE69408873T2 (de) | 1993-12-22 | 1998-07-09 | Shell Int Research | Verfahren zur herstellung von carbamaten |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| US6503713B1 (en) | 1999-10-04 | 2003-01-07 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying RNA binding compounds |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| AU2005214376A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| CA2589877A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| US20080255150A1 (en) | 2005-11-05 | 2008-10-16 | Astrazeneca Ab | Novel Compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| ES2433235T3 (es) | 2009-11-03 | 2013-12-10 | Bayer Intellectual Property Gmbh | Fluorouretanos como aditivos en una formulación de fotopolímero |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| US10570146B2 (en) | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PL3541807T3 (pl) * | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | Krystaliczna postać inhibitora magl |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| RU2020107039A (ru) | 2017-08-29 | 2021-09-30 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Спироциклические соединения и способы их получения и применения |
| MA52635A (fr) | 2018-05-15 | 2021-03-24 | H Lundbeck As | Inhibiteurs de magl |
| SG11202108008PA (en) | 2019-01-25 | 2021-08-30 | H Lundbeck As | Methods of treating disease with magl inhibitors |
-
2019
- 2019-05-14 MA MA052635A patent/MA52635A/fr unknown
- 2019-05-14 EA EA202092586A patent/EA202092586A1/ru unknown
- 2019-05-14 CN CN201980031137.4A patent/CN112088001A/zh active Pending
- 2019-05-14 SG SG11202011228TA patent/SG11202011228TA/en unknown
- 2019-05-14 WO PCT/US2019/032289 patent/WO2019222266A1/en not_active Ceased
- 2019-05-14 BR BR112020000863-0A patent/BR112020000863A2/pt not_active Application Discontinuation
- 2019-05-14 TW TW108116518A patent/TW201946906A/zh unknown
- 2019-05-14 EP EP19803143.7A patent/EP3793547A4/en not_active Withdrawn
- 2019-05-14 AU AU2019271123A patent/AU2019271123A1/en not_active Abandoned
- 2019-05-14 US US17/055,079 patent/US11332453B2/en not_active Expired - Fee Related
- 2019-05-14 US US16/412,212 patent/US10570106B2/en not_active Expired - Fee Related
- 2019-05-14 CA CA3097063A patent/CA3097063A1/en active Pending
- 2019-05-14 JP JP2020564158A patent/JP2021523200A/ja not_active Ceased
- 2019-05-14 GE GEAP201915479A patent/GEP20227443B/en unknown
- 2019-05-14 MX MX2020012158A patent/MX2020012158A/es unknown
- 2019-05-14 AR ARP190101283A patent/AR115092A1/es not_active Application Discontinuation
- 2019-05-14 CR CR20200545A patent/CR20200545A/es unknown
- 2019-05-14 GE GEAP202215479A patent/GEAP202215479A/en unknown
- 2019-05-14 PE PE2020001853A patent/PE20211385A1/es unknown
- 2019-05-14 JO JOP/2020/0276A patent/JOP20200276A1/ar unknown
- 2019-05-14 KR KR1020207033709A patent/KR20210010475A/ko not_active Ceased
-
2020
- 2020-01-10 US US16/739,642 patent/US11214557B2/en not_active Expired - Fee Related
- 2020-10-12 ZA ZA2020/06327A patent/ZA202006327B/en unknown
- 2020-10-28 CO CONC2020/0013550A patent/CO2020013550A2/es unknown
- 2020-11-10 DO DO2020000207A patent/DOP2020000207A/es unknown
- 2020-11-11 CL CL2020002927A patent/CL2020002927A1/es unknown
- 2020-11-13 PH PH12020551934A patent/PH12020551934A1/en unknown
- 2020-11-13 NI NI202000080A patent/NI202000080A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019116512A (ru) | Ингибиторы magl | |
| JP2021514001A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| RU2019115784A (ru) | Ингибиторы magl | |
| RU2019116514A (ru) | Ингибиторы magl | |
| JP2019531279A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| JP2018504437A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2020532545A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| RU2020107039A (ru) | Спироциклические соединения и способы их получения и применения | |
| JP2022529311A5 (enExample) | ||
| JP2020511536A5 (enExample) | ||
| JP2022141692A5 (enExample) | ||
| JP2023518044A5 (enExample) | ||
| JP2024532249A5 (enExample) | ||
| JP2021046404A5 (enExample) | ||
| JP2020504184A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2012518634A5 (enExample) | ||
| JP2017531016A5 (enExample) |